Hydroxocobalamin
Established medicineAlso known as Calafol Rx, Cyanokit, Folpace Rx, Hydro Cobex+7 more
Calafol Rx, Cyanokit, Folpace Rx, Hydro Cobex, Hydro-Cobex, Hydroxy Cobal, Hydroxy-Cobal, OH-Cbl, Vitamin B12a, Hydroxocobalamine, Hydroxycobalamin.
Recent clinical, regulatory, research and industry developments relating to this drug.
A Phase II Double Blind Randomized Controlled Trial of High Dose Vitamin B12 in Septic Shock
A Study on Hydroxocobalamin Given to Healthy Individual to Monitor Symptoms
Vitamin Deficiencies and Suppletion in Morbid Obesity
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Treatment of known or suspected cyanide poisoning. Cyanokit is to be administered together with appropriate decontamination and supportive measures.
Evidence ↗Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.